NCT05016323View on ClinicalTrials.gov

A Study to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Primary IgA Nephropathy.

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

316

Participants

Timeline

Start Date

September 9, 2021

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2025

Conditions

IgA Nephropathy

Interventions

DRUG

HR19042 Capsules

HR19042 Capsules

DRUG

Placebo

Placebo

Trial Locations (1)

510515

NanFang Hospital of Southern Medical University, Guangzhou

All Listed Sponsors

lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY